Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1653015

registered interest
date	13/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether Market Authorisation Holders set different (1) Key Performance Indicator measurements, and (2) clinical pathways, for the same therapy.
tabling member printed	Lord Blencathra
uin	HL9314
answer	answer is ministerial correction date of answer 26/07/2023 answer text <p>Marketing Authorisation Holders (MAHs) are encouraged to use the national Key Performance Indicators (KPIs) published in the Royal Pharmaceutical Homecare Services Handbook 2014 in their contracts with homecare providers. MAHs may also use additional or alternative specific KPIs where they consider this necessary. Neither NHS England nor National Health Service trusts are directly party to those contracts between MAHs and homecare providers, and therefore do not have visibility of the KPIs agreed in each case.</p><p>The treatment choice is determined by the clinician in the hospital trust in conversation with the patient, based on the best available evidence and cost-effectiveness aligned to national and local guidance where available. The homecare medicines service provider is contracted to undertake supply and delivery, and administration in some cases. The homecare medicines service provider does not determine the clinical pathway.</p> answering member printed Lord Markham question first answered 26/07/2023 13:33:48 answering member 4948 label Biography information for Lord Markham
tabling member	497 label Biography information for Lord Blencathra

1642808

registered interest
date	07/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the remarks by Lord Markham on 25 May (HL Deb col 1032), whether the National Institute for Health and Care Excellence is currently considering changing the reference case discount rate for costs and health effects that is applied to new health technologies.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8289
answer	answer is ministerial correction date of answer 22/06/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses in the development of its guidance, including the discount rate, taking into account its responsibilities under Managing Public Money.</p><p>NICE concluded a comprehensive review of its methods and processes in 2022, including consideration of the discount rate. Following public consultation, NICE concluded that it was appropriate to maintain the existing rate of 3.5% due to policy and fiscal implications and interdependencies beyond the scope of the review. The Department and HM Treasury were engaged throughout the review.</p><p>NICE is introducing a new modular approach for further methods updates, where it will work with its system partners on the methodological priorities for the healthcare system.</p> answering member printed Lord Markham grouped question UIN HL8290 question first answered 22/06/2023 15:59:34 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1642809

registered interest
date	07/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the remarks by Lord Markham on 25 May (HL Deb col 1032), whether decisions about changes to the reference case discount rate applied to new technologies for costs and health effects are a matter solely for the National Institute for Health and Care Excellence.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8290
answer	answer is ministerial correction date of answer 22/06/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses in the development of its guidance, including the discount rate, taking into account its responsibilities under Managing Public Money.</p><p>NICE concluded a comprehensive review of its methods and processes in 2022, including consideration of the discount rate. Following public consultation, NICE concluded that it was appropriate to maintain the existing rate of 3.5% due to policy and fiscal implications and interdependencies beyond the scope of the review. The Department and HM Treasury were engaged throughout the review.</p><p>NICE is introducing a new modular approach for further methods updates, where it will work with its system partners on the methodological priorities for the healthcare system.</p> answering member printed Lord Markham grouped question UIN HL8289 question first answered 22/06/2023 15:59:34 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1579865

registered interest
date	23/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether it is his policy to work with (a) patient groups, (b) industry stakeholders and (c) other relevant parties on finding solutions to the challenges of patient access to combination therapy treatments, including (i) a lack of framework for multi-indication pricing, (ii) rigid cost-effectiveness frameworks and (iii) legal barriers.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	129952
answer	answer is ministerial correction date of answer 30/01/2023 answer text <p>The Department wants patients to benefit from access to effective new treatments at a price that represents value and is fair to all parties. The National Institute for Health and Care Excellence (NICE) has been able to recommend over 95% of the combination therapies on which it published technology appraisal guidance between 2017 and 2022. NICE is developing a modular approach to its methods and process updates and potential topics will be considered by NICE taking into account all relevant factors.</p><p>NHS England’s Commercial Framework for New Medicines recognises that realising the full potential health benefits from combination drug therapies can be challenging given the requirement for commercial confidentiality and the need to maintain competition.</p><p>Alongside NICE, NHS England has been supporting the Association of the British Pharmaceutical Industry (ABPI) efforts to find solutions to enable companies to engage with one another where health-improving combination therapies face challenges coming to market.</p><p>In the United Kingdom, the Competition and Markets Authority represents the sole competent authority, and the commercial aspects of bringing combination therapies to the market must be compliant with relevant legislation.</p><p>There are currently no plans to establish a task and finish group.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 129956 129957 question first answered 30/01/2023 17:10:30 answering member 4423 label Biography information for Will Quince
tabling member	4398 label Biography information for Chris Green

1579866

registered interest
date	23/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether policies to improve patient access to combination therapies will be considered by his Department in upcoming negotiations for the 2024 Voluntary Scheme for Branded Medicines Pricing and Access.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	129953
answer	answer is ministerial correction date of answer 30/01/2023 answer text <p>The Department is considering how a successor to the voluntary scheme for branded medicines pricing and access should operate from 2024 onwards and will work with industry to agree a mutually beneficial successor that that supports better patient outcomes, ensuring the sustainability of National Health Service spend on branded medicines and enables a strong United Kingdom life sciences industry.</p> answering member constituency Colchester answering member printed Will Quince question first answered 30/01/2023 17:02:55 answering member 4423 label Biography information for Will Quince
tabling member	4398 label Biography information for Chris Green

1579868

registered interest
date	23/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what percentage of health technology appraisals conducted by NICE for therapies in combination have resulted in (a) termination, (b) a negative recommendation, (c) an optimised recommendation, (d) a positive recommendation or (e) a recommendation for use within the Cancer Drugs Fund or Innovative Medicines Fund.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	129955
answer	answer is ministerial correction date of answer 02/02/2023 answer text <p>Between 1 January 2017 and 31 December 2022, 20% of appraisals of combination therapies undertaken by the National Institute for Health and Care Excellence (NICE) were terminated due to the company not making an evidence submission to NICE.</p><p>Of the technologies appraised by NICE, 4% were not recommended, 31% were recommended for routine commissioning, 52% were optimised recommendations and 12% were recommended or optimised for use within the Cancer Drugs Fund.</p><p>No applications were recommended for the Innovative Medicines fund.</p> answering member constituency Colchester answering member printed Will Quince question first answered 02/02/2023 15:21:00 answering member 4423 label Biography information for Will Quince
tabling member	4398 label Biography information for Chris Green

1551539

registered interest
date	14/12/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has held recent discussions with the National Institute for Health and Care Excellence on changing the discount rate; what his planned timetable is for this work; and whether it will be subject to formal public consultation.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	110708
answer	answer is ministerial correction date of answer 22/12/2022 answer text <p>There have been no recent discussions. The National Institute for Health and Care Excellence (NICE) concluded a review of its methods and processes for health technology evaluation, including consideration of the discount rate and published its updated manual on 31 January 2022. NICE’s final consultation on proposed changes closed on 13 October 2021. NICE concluded that while there was some evidence to support a change to the reference case discount rate, it was appropriate to maintain the existing rate of 3.5% due to policy and fiscal implications and interdependencies beyond the scope of the review.</p> answering member constituency Colchester answering member printed Will Quince question first answered 22/12/2022 10:56:17 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1523380

registered interest
date	18/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will take steps with Cabinet colleagues to support companies to (a) develop and (b) deploy life-saving health technology solutions.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	65781
answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>We are supporting companies to develop and deploy health technologies, including the Data for Research and Development Programme to make research-ready data available to innovators in a streamlined and secure way. The Artificial Intelligence in Health and Care Award provides funding and practical support to the most promising AI technologies, including 30 which are being deployed for testing and the small Business Research Initiative Healthcare Award programme supports innovators and entrepreneurs in health and social care.</p><p>‘A plan for digital health and social care’ published in June 2022 also set out how we are developing and embedding technology and digital solutions in the National Health Service.</p> answering member constituency Colchester answering member printed Will Quince question first answered 01/11/2022 11:54:10 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1485909

registered interest
date	04/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 June (HL645), whether an agenda for NHS England's Clinical Priorities Advisory Group's next meeting has been finalised; and if so, when it will be shared with relevant stakeholders.
tabling member printed	Baroness Masham of Ilton
uin	HL1440
answer	answer is ministerial correction date of answer 18/07/2022 answer text <p>The agenda has been finalised and made available to relevant stakeholders.</p> answering member printed Lord Kamall grouped question UIN HL1396 question first answered 18/07/2022 15:01:12 answering member 4909 label Biography information for Lord Kamall
tabling member	1850 label Biography information for Baroness Masham of Ilton

1485232

registered interest
date	30/06/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 June (HL645), whether an agenda for NHS England's Clinical Priorities Advisory Group's next meeting has been finalised; and if so, when the agenda will be shared with stakeholders.
tabling member printed	Baroness Masham of Ilton
uin	HL1396
answer	answer is ministerial correction date of answer 18/07/2022 answer text <p>The agenda has been finalised and made available to relevant stakeholders.</p> answering member printed Lord Kamall grouped question UIN HL1440 question first answered 18/07/2022 15:01:12 answering member 4909 label Biography information for Lord Kamall
tabling member	1850 label Biography information for Baroness Masham of Ilton